Skip to main content

Advertisement

Log in

Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To determine the value of combined 18F-FDG PET/CT with diagnostic contrast-enhanced CT (CECT) in detecting primary malignancies and metastases in patients with paraneoplastic neurological syndromes (PNS) and to compare this with CECT alone.

Methods

PET/CT scans from 66 patients with PNS were retrospectively evaluated. Two blinded readers initially reviewed the CECT portion of each PET/CT scan. In a second session 3 months later, the readers analysed the combined PET/CT scans. Findings on each study were assessed using a four-point-scale (1 normal/benign; 2 inconclusive, further diagnostic work-up may be necessary; 3 malignant; 4 inflammatory). Sensitivity and specificity for malignant findings were calculated for PET/CT and CECT. Interreader agreement was determined by calculating Cohen’s kappa. Pooled data from clinical follow-up (including histopathology and follow-up imaging, median follow-up 20.0 months) served as the reference gold standard.

Results

Both readers classified 12 findings in ten patients (15 %) as malignant on the PET/CT scans (two patients had two primary tumours). One such imaging finding (suspected thymic cancer) was false-positive (i.e. benign histology). The most common tumours were bronchial carcinoma (n = 3), lymph node metastases of gynaecological tumours (n = 3) and tonsillar carcinoma (n = 2). Three of 12 findings (25 %) were not detected by CECT alone (cervical carcinoma, lymph node metastasis and tonsillar carcinoma). In a per-patient analysis, sensitivity and specificity for malignant findings were 100 % and 90 % for PET/CT and 78 % and 88 % for CECT. In 24 % (reader 1) and 21 % (reader 2) of the patients, the PET/CT findings were inconclusive. Of these findings, 57 % (reader 1) and 56 % (reader 2) were only diagnosed with PET (e.g. focal FDG uptake of the thyroid, gastrointestinal tract and ovaries). On follow-up, none of these findings corresponded to malignancy. Overall agreement between the two readers was excellent with a Cohen’s kappa of 0.95 ± 0.04 (p < 0.001) for PET/CT and 0.97 ± 0.03 (p < 0.001) for CECT alone.

Conclusion

In this cohort of patients with PNS, PET/CT exhibited improved detection of underlying malignancy versus CECT alone. While hybrid imaging produces a greater number of inconclusive findings, sensitivity is increased for the detection of head and neck and gynaecological malignancies as well as metastatic lymph node involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–5.

    Google Scholar 

  2. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45 Suppl 1:56S–65S.

    PubMed  CAS  Google Scholar 

  3. Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanché JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48:105–8.

    Article  PubMed  CAS  Google Scholar 

  4. Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010;20:923–30.

    Article  PubMed  Google Scholar 

  5. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–9.

    PubMed  Google Scholar 

  6. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008;49:17N–21N 37N.

    Article  PubMed  Google Scholar 

  7. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–164.

    Article  PubMed  CAS  Google Scholar 

  8. Cashman EC, Macmahon PJ, Shelly MJ, Kavanagh EC. Role of positron emission tomography-computed tomography in head and neck cancer. Ann Otol Rhinol Laryngol. 2011;120:593–602.

    PubMed  Google Scholar 

  9. Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings AJR Am J Roentgenol 1998;170:1513–157.

    Article  PubMed  CAS  Google Scholar 

  10. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–40.

    Article  PubMed  Google Scholar 

  11. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–54.

    Article  PubMed  CAS  Google Scholar 

  12. Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol. 2005;252:197–201.

    Article  PubMed  Google Scholar 

  13. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.

    Article  PubMed  CAS  Google Scholar 

  14. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.

    Article  PubMed  CAS  Google Scholar 

  15. Hadjivassiliou M, Alder SJ, Van Beek EJ, Hanney MB, Lorenz E, Rao DG, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand. 2009;119:186–93.

    Article  PubMed  CAS  Google Scholar 

  16. Keime-Guibert F, Graus F, Fleury A, René R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:479–82.

    Article  PubMed  CAS  Google Scholar 

  17. Kumar A, Regmi SK, Dutta R, Kumar R, Gupta SD, Das P, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med. 2009;23:569–77.

    Article  PubMed  Google Scholar 

  18. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282–6.

    Article  PubMed  Google Scholar 

  19. Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol. 2007;62:328–34.

    Article  PubMed  Google Scholar 

  20. Liu RS, Yeh SH, Huang MH, Wang LS, Chu LS, Chang CP, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med. 1995;22:1402–7.

    Article  PubMed  CAS  Google Scholar 

  21. Matsuhisa A, Toriihara A, Kubota K, Makino T, Mizusawa H, Shibuya H, et al. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes. Clin Nucl Med. 2012;37:39–43.

    Article  PubMed  Google Scholar 

  22. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR, et al. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008;83:917–22.

    PubMed  Google Scholar 

  23. Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124:2223–31.

    Article  PubMed  CAS  Google Scholar 

  24. Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:713–5.

    Article  PubMed  CAS  Google Scholar 

  25. Rosenfeld MR, Dalmau J. Update on paraneoplastic neurologic disorders. Oncologist. 2010;15:603–17.

    Article  PubMed  Google Scholar 

  26. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000;23:1800–18.

    Article  PubMed  CAS  Google Scholar 

  27. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19–e13.

    Article  PubMed  CAS  Google Scholar 

  28. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276–81.

    Google Scholar 

  29. Tsujikawa T, Tsuchida T, Yoshida Y, Kurokawa T, Kiyono Y, Okazawa H, et al. Role of PET/CT in gynecological tumors based on the revised FIGO staging classification. Clin Nucl Med. 2011;36:e114–8.

    Article  PubMed  Google Scholar 

  30. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682–90.

    Article  PubMed  CAS  Google Scholar 

  31. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1:294–305.

    Article  PubMed  Google Scholar 

  32. Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Schramm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schramm, N., Rominger, A., Schmidt, C. et al. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT. Eur J Nucl Med Mol Imaging 40, 1014–1024 (2013). https://doi.org/10.1007/s00259-013-2372-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2372-4

Keywords

Navigation